PI3K inhibition to overcome endocrine resistance in breast cancer

Pharmacology, Toxicology and Pharmaceutical Science

• Phosphatidylinositol 3 Kinase 100%
• Biological Marker 100%
• Breast Cancer 100%
• Phosphatidylinositol 3 Kinase Inhibitor 100%
• Clinical Trial 33%
• Carcinogenesis 33%
• Estrogen Receptor 33%
• Endocrine Therapy 33%
• Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer 33%
• Estrogen Receptor Positive Breast Cancer 33%
• Therapy Resistance 33%